Literature DB >> 22999874

Fine-tuning S1P therapeutics.

Hideru Obinata, Timothy Hla.   

Abstract

Sphingosine 1-phosphate receptor-1 (S1P(1)), a novel therapeutic target for multiple sclerosis, regulates lymphocyte trafficking, heart rate, and vascular function. The discovery of NIBR-0213, a competitive antagonist for S1P(1) that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue of Chemistry & Biology), suggests that fine-tuning of S1P(1) modulators may lead to novel immune modulators with better efficacy to adverse events ratio.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2012        PMID： 22999874      PMCID： PMC3625427          DOI： 10.1016/j.chembiol.2012.09.002

Source DB:  PubMed          Journal:  Chem Biol        ISSN： 1074-5521


  11 in total

1.  Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists.

Authors:  Frank W Foss; Ashley H Snyder; Michael D Davis; Michael Rouse; Mark D Okusa; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem       Date:  2006-11-01       Impact factor: 3.641

Review 2.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

3.  The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.

Authors:  Lev Koyrakh; Maria I Roman; Volker Brinkmann; Kevin Wickman
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

4.  Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

Authors:  M Germana Sanna; Sheng-Kai Wang; Pedro J Gonzalez-Cabrera; Anthony Don; David Marsolais; Melanie P Matheu; Sindy H Wei; Ian Parker; Euijung Jo; Wei-Chieh Cheng; Michael D Cahalan; Chi-Huey Wong; Hugh Rosen
Journal:  Nat Chem Biol       Date:  2006-07-09       Impact factor: 15.040

5.  Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.

Authors:  Myat Lin Oo; Shobha Thangada; Ming-Tao Wu; Catherine H Liu; Timothy L Macdonald; Kevin R Lynch; Chen-Yong Lin; Timothy Hla
Journal:  J Biol Chem       Date:  2007-01-21       Impact factor: 5.157

Review 6.  Modulating tone: the overture of S1P receptor immunotherapeutics.

Authors:  Hugh Rosen; Pedro Gonzalez-Cabrera; David Marsolais; Stuart Cahalan; Anthony S Don; M Germana Sanna
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 7.  Sphingosine 1-phosphate in coagulation and inflammation.

Authors:  Hideru Obinata; Timothy Hla
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

8.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.

Authors:  Christina Christoffersen; Hideru Obinata; Sunil B Kumaraswamy; Sylvain Galvani; Josefin Ahnström; Madhumati Sevvana; Claudia Egerer-Sieber; Yves A Muller; Timothy Hla; Lars B Nielsen; Björn Dahlbäck
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

9.  A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.

Authors:  Jean Quancard; Birgit Bollbuck; Philipp Janser; Daniela Angst; Frédéric Berst; Peter Buehlmayer; Markus Streiff; Christian Beerli; Volker Brinkmann; Danilo Guerini; Paul A Smith; Timothy J Seabrook; Martin Traebert; Klaus Seuwen; René Hersperger; Christian Bruns; Frédéric Bassilana; Marc Bigaud
Journal:  Chem Biol       Date:  2012-09-21

10.  Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics.

Authors:  Shobha Thangada; Kamal M Khanna; Victoria A Blaho; Myat Lin Oo; Dong-Soon Im; Caiying Guo; Leo Lefrancois; Timothy Hla
Journal:  J Exp Med       Date:  2010-06-28       Impact factor: 14.307
View more
  7 in total

1.  Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.

Authors:  Hideru Obinata; Sarah Gutkind; Jeremiah Stitham; Toshiaki Okuno; Takehiko Yokomizo; John Hwa; Timothy Hla
Journal:  J Lipid Res       Date:  2014-10-07       Impact factor: 5.922

2.  Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury.

Authors:  Dengpiao Xie; Gaizun Hu; Chaoling Chen; Fereshteh Ahmadinejad; Weili Wang; Pin-Lan Li; David A Gewirtz; Ningjun Li
Journal:  Am J Physiol Renal Physiol       Date:  2022-07-14

Review 3.  Emerging targets in lipid-based therapy.

Authors:  Stephanie C Tucker; Kenneth V Honn
Journal:  Biochem Pharmacol       Date:  2012-12-20       Impact factor: 5.858

4.  A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury.

Authors:  Hongjun Jin; Hao Yang; Hui Liu; Yunxiao Zhang; Xiang Zhang; Adam J Rosenberg; Yongjian Liu; Suzanne E Lapi; Zhude Tu
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952

5.  The role of sphingosine-1 phosphate and ceramide-1 phosphate in trafficking of normal stem cells and cancer cells.

Authors:  Mariusz Z Ratajczak; Malwina Suszynska; Sylwia Borkowska; Janina Ratajczak; Gabriela Schneider
Journal:  Expert Opin Ther Targets       Date:  2013-11-04       Impact factor: 6.902

Review 6.  Intercellular Lipid Mediators and GPCR Drug Discovery.

Authors:  Dong-Soon Im
Journal:  Biomol Ther (Seoul)       Date:  2013-11       Impact factor: 4.634

7.  Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction.

Authors:  Mallika Ghosh; Shobha Thangada; Oisharya Dasgupta; Kamal M Khanna; Harold T Yamase; Michael Kashgarian; Timothy Hla; Linda H Shapiro; Fernando A Ferrer
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.